Reader Remarks on:

Short-Term vs. Long-Term Hormone Therapy for Prostate Cancer

Duration of ADT in PC

Duration of ADT in PC

SB Strum, Ashland, OREGON, 15 Jun 2009 7:25 AM EST

Competing interests: None declared

The observation is important but students of ADT know that the depth of the PSA nadir on ADT is an excellent indicator of subsets of patients that will not optimally respond to ADT and who need a change in treatment strategy, rather then lumping such patients into a prolonged treatment with ADT which is not without its side effects. Our paper (reference below) details such information & indicates that failure to reach a PSA nadir of 0.05 or less selects patients who are at major risk for cancer-specific mortality.

Scholz M, Lam R, Strum S, et al: Prostate cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone inactivating pharmaceuticals. Urology 70:506-10, 2007.

Stephen B. Strum, MD, FACP Medical Oncologist specializing in PC

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. Please consider this when composing your remark.

Remark subject:*

Your remark:*

Fields marked with an * are required.

Name as you'd like it to appear:
First & middle initial:*

Last:*

Email address (will not
be published):*

Place of work (optional):

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

No competing interests

Or, the following competing interests:

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.

Search

Sign-In

Forgot your password?

New to Journal Watch?